Overview

* AxoGen ( AXGN ) Q3 revenue rises 23.5% yr/yr to $60.1 mln, beating analyst expectations

* Adjusted EPS for Q3 beats consensus

* Company reports net income of $0.7 mln, reversing a loss from last year

Outlook

* Company raises full-year revenue growth guidance to at least 19%, or $222.8 mln

* Company expects full-year gross margin between 73% and 75%

* FDA approval of Avance Nerve Graft BLA anticipated by December 5, 2025

Result Drivers

* BROAD-BASED GROWTH - Revenue growth was broad-based with double-digit increases across all markets, including Extremities, Oral Maxillofacial & Head and Neck, and Breast

* EXPANDED COVERAGE - Increased coverage and reimbursement for nerve repair procedures added 1.1 mln covered lives, enhancing market access

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $60.10 $56.80

Revenue mln mln (9

Analysts

)

Q3 Beat $0.12 $0.07 (6

Adjusted Analysts

EPS )

Q3 $6.10

Adjusted mln

Net

Income

Q3 Net $700,000

Income

Q3 $9.20

Adjusted mln

EBITDA

Q3 Gross 76.60%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for AxoGen Inc ( AXGN ) is $25.00, about 27.7% above its October 28 closing price of $18.08

* The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)